Lamivudine/nevirapine/stavudine
| Combination of | |
|---|---|
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Nevirapine | non-nucleoside reverse transcriptase inhibitor |
| Stavudine | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Triomune, others |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a
It is on the World Health Organization's List of Essential Medicines.[2] As of 2015, it is not commercially available in the United States.[3]
Medical uses
It is a common first line treatment in the
developing world.[4]
Adverse effects and safety
The medication is generally well tolerated.second trimester if possible.[5]
References
- ^ ISBN 9789241547659.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ISBN 9780071802161. Archivedfrom the original on 2016-12-20.
- PMID 16625606.
- ^ a b c d "Nevirapine/stavudine/lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
External links
- "Lamivudine mixture with Nevirapine and Stavudine". Drug Information Portal. U.S. National Library of Medicine.
